Prostate Single Port & Laser Enucleation Comparison Trial
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jan 23, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Prostate Single Port & Laser Enucleation Comparison Trial, is studying two different surgical methods to treat men with benign prostatic hyperplasia (BPH), a condition where the prostate gland becomes enlarged and causes difficulties with urination. The trial will compare a newer technique called single-port robotic surgery using the da Vinci system to a traditional method called thulium laser enucleation. Both methods are designed to relieve urinary symptoms and improve quality of life for men who have not found relief from medication.
To participate in this study, men aged 65 to 74 who have been diagnosed with BPH and have not responded well to medication may be eligible. However, individuals with certain conditions, such as cognitive impairment or blood disorders, will not be able to take part. If you enroll in the trial, you can expect to undergo one of the two surgical procedures, and the outcomes will be closely monitored to see which method works better for relieving symptoms. This research could help improve treatment options for future patients facing similar challenges.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention.
- Exclusion Criteria:
- • Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Simone Crivellaro, MD
Principal Investigator
University of Illinois at Chicago, Department of Urology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported